A double-blind, randomised, parallel-group trial was cant falls in heart rate. Both active drugs were well tolerconducted in patients with essential hypertension in ated, nebivolol marginally more so. Nebivolol, a longBritish general practices, of nebivolol 5 mg, atenolol acting, cardioselective, vasodilating beta-blocker which 50 mg, and placebo each given once daily. Both active acts partly via the l-arginine/nitric oxide mechanism, drugs, in comparison with placebo, caused highly sigappears potentially valuable for the treatment of hypernificant and similar reductions in systolic and diastolic tension. pressures without orthostatic effect, and small signifiKeywords: nitric oxide; quality of life; side effects daily were begun. After 4 weeks of this single-blind
Introduction
placebo run-in, those with a sitting diastolic pressNebivolol is a highly cardioselective beta-blocking ure of at least 95 mm Hg and at most 115 mm Hg agent devoid of intrinsic sympathomimetic activity, could enter the trial proper. A previous dosewith vasodilating properties and a prolonged action; response trial of nebivolol had shown that 5 mg it acts in part via the l-arginine/nitric oxide pathonce daily in hypertensive patients controlled blood way. At similar anti-hypertensive doses, nebivolol pressure (BP) over 24 h; no additional effect was has been found to exert less beta-1 blockade than do seen with 10 mg. 10 Likewise, atenolol 50 mg once standard beta-blockers, as judged by the extent of daily had earlier been found to be as effective as reduction of exercise-induced tachycardia. [1] [2] [3] [4] [5] [6] [7] [8] [9] This 100 mg. 11 Thus the doses of active drugs used were paper reports a double-blind randomised trial of nebivolol 5 mg and atenolol 50 mg. Patients were once-daily nebivolol compared with once-daily randomised via a computer-generated list to receive, atenolol, a well established cardioselective betadouble-blind, once-daily placebo, or nebivolol 5 mg, blocker and placebo, in essential hypertension.
or atenolol 50 mg, for the trial duration of 1 month, further visits being scheduled at 2 weeks and at the
Patients and methods
end of this time. If after 2 weeks of the double-blind treatment the diastolic pressure was Ͼ120 mm Hg, The trial was conducted in patients under primary or the systolic Ͼ220 mm Hg, patients were withmedical care (general practice) in Britain. Male and drawn and considered as non-responders. Patients female ambulatory subjects, between the ages of 18 could also withdraw at any time should they wish; and 71 years, with mild-to-moderate essential or for any reason at the discretion of the investigator, hypertension, were eligible; those previously or if a serious adverse event occurred. untreated, or who had responded poorly or were All trial medication consisted of tablets identical intolerant of previous treatment, could be recruited.
in appearance and taste. Patients were instructed to Exclusion criteria are listed in Table 1 . Those take one tablet once daily at breakfast, except on the entering were required to give informed consent. At occasion of clinic visits, when medication was omitthe screening visit, initial assessments were performed, candidate patients were asked to discontinue ted until after BP had been taken. Thus the BP any current anti-hypertensive drugs within the next values reported (Figures 1-4 ) are those obtained 23-2 weeks, while single-blind placebo tablets once 25 h after dosing. Drugs that might interfere with the anti-hypertensive effect of the trial medication were not allowed (see Table 1 ). was assessed by tablet count at the end of the Table 1 Exclusion criteria ț secondary hypertension, or malignant hypertension (retinal haemorrhage, exudates or papillary oedema) ț asthma or chronic obstructive airway disease ț bradycardia (less than 60 beats per minute at rest) ț atrial fibrillation or recurrent tachyarrhythmia requiring antiarrhythmic therapy ț insulin dependent diabetes ț history of sensitivity or severe adverse reaction to beta-blockers ț myocardial infarction or cerebrovascular accident within the last 6 months ț heart failure requiring treatment, or valvular disease of haemodynamic significance ț severe renal or hepatic disease (urine protein Ͼ trace, creatinine Ͼ 2.2 mg/dl or Ͼ 200 Tmol/l, ASAT and/or ALAT greater than twice the upper normal limit) ț (possible) pregnancy or nursing ț any concurrent condition that could, according to the investigator, jeopardise participant adherence to the protocol or ability to complete the trial (eg, alcohol or drug abuse, disabling or terminal illness, personality or mental disorders) ț concurrent therapy with medications that could affect blood pressure (therapy with tricyclic antidepressants drugs or MAO inhibitors; corticosteroids or non-steroidal anti-inflammatory drugs, if used regularly; hormonal contraceptives) ț investigational drug treatment within the past 120 days ț predictable lack of co-operation double-blind trial period. Major dietary changes, eg, taneously, or if recalled in response to the standard question, 'Has treatment upset you in any way?'. for weight reduction or salt restriction, were not permitted during the trial.
Positive experiences were recorded if reported spontaneously, or in response to the standard question, Systolic and diastolic pressures were recorded, using a random-zero sphygmomanometer, taking 'Did you experience any beneficial effect from treatment?'. A quality of life questionnaire comprising Korotkoff phases 1 and 5, respectively. In each patient, measurements were made by the same 91 questions was completed by a subset of patients at the end of the 4-week double-blind period. A 12-investigator or member of the investigator's staff, in the same room and at the same time of day, preferlead electrocardiogram was recorded at screening, at the end of the placebo run-in, and at the end of the ably in the morning. At the first visit BP was determined in both arms; if a difference of Ͼ4 mm Hg was double-blind treatment period. Routine haematological, biochemical, and urine tests were performed at found, the arm with the higher pressure was used throughout, otherwise the right arm was always screening, at the end of the placebo run-in, and at the end of the double-blind treatment period. employed. The sphygmomanometer cuff was at least 30 cm long and 13 cm wide; if the arm circumferOn the assumption that a difference in supine diastolic pressure by a mean ± s.d. of 5 mm Hg ± ence exceeded 34 cm, an appropriately larger cuff was used. Sitting BP was taken after the patient had 11.5 would occur between placebo and at least one of the other treatment groups, it was calculated that rested for 5 min; standing pressure after 2 min of standing. Heart rate was counted sitting and standa total of 414 patients (138 per treatment group) would be needed to detect the difference with a 5% ing. At each visit patients were weighed partially clothed.
two-tailed significance and 95% power. The primary pre-declared index variable was sitAdverse events were noted if mentioned spon- ting diastolic pressure at 'trough' drug level, 23-25 h decrease in sitting diastolic pressure at trough drug level to 90 mm Hg or below. The 2 test was used to from the previous intake of medication, using the last available reading in each patient (end-point), detect between-group differences for the percentages of responders. The quality of life questionnaire was whether or not that patient completed the intended full trial duration. An 'intent to treat' analysis was evaluated descriptively and by non-parametric test (Wilcoxon-Mann-Whitney U-test). performed, that is, all randomised patients, regardless of their compliance with the protocol, were included. Treatment effects were evaluated at a twoResults tailed 5% significance level by means of a one-way analysis of variance. If the overall comparison was A total of 366 patients entered the run-in period, ie, slightly fewer than were intended from the above significant, multiple comparisons were made by Dunnett's t-test to assess differences between nebivstatistical considerations. Of these, two dropped out before randomisation. Of the remainder, 119 were olol and placebo and between nebivolol and atenolol. Response rate (normalisation) was defined as a allocated to nebivolol, 121 to atenolol and 124 to placebo. The characteristics of the patients at given. It can be seen that by 2 weeks, and then throughout the period of active therapy, both nebivrandomisation are shown in Table 2 . The three treatment groups were broadly similar in all relevant olol and atenolol lowered both systolic and diastolic pressures significantly (P Ͻ 0.001) in comparison features; the racial composition was overwhelmingly Caucasian. It is apparent from Table 2 that 17 with placebo, but with no appreciable differences in effect between the two drugs. Both active drugs prepatients at entry showed BP outwith the predefined trial limits; four below and 13 above. Tablet count served the slight rise in diastolic pressure which occurs normally on standing. The percentages of indicated that all except one patient on atenolol took at least 80% of the prescribed medication during the pre-defined responders were nebivolol 59%, atenolol 59% and placebo 29% (both active drugs P Ͻ double-blind treatment period.
The systolic and diastolic pressures sitting and 0.001 vs placebo). As expected, resting (sitting) heart rate fell sigstanding through the trial at 'trough' drug levels in the three treatment groups are shown in Figures 1-nificantly with active treatment; at end-point vs placebo by a mean of 7.8 beats per minute on nebivolol 4. The numbers of patients in each group contributing to the measurements at each time point are also and 7.7 on atenolol (both P Ͻ 0.001 vs placebo). No significant intergroup differences. a Data on weight, body mass index and low salt diet not available in some patients (no more than one patient in any group).
There were no significant changes in body weight Both active drugs were well tolerated, nebivolol marginally more so. Earlier work showed that at during the trial in any of the three treatment groups.
During double-blind therapy, adverse events were similar anti-hypertensive doses to standard betablockers, nebivolol exerted less beta-1 blockade, reported by 33 (28%) of nebivolol patients, 37 (31%) of atenolol patients and by 31 (25%) on placebo. The assessed by the capacity to limit exercise-induced tachycardia. 1, 2, 4, 5 However, resting heart rate, by only notable treatment-related complaint was fatigue, which was reported during the double-blind contrast, was in the present trial, lowered similarly by nebivolol and atenolol. phase in four nebivolol and eight atenolol patients and in one placebo patient. There were at baseline Nebivolol possesses several properties which are potentially attractive in the treatment of hypertendifferences in the frequency of adverse events in the three groups. During the double-blind treatment persion. It acts partly through the l-arginine/nitric oxide pathway, has vasodilating effects, and iod, the increase in fatigue was found to be more prominent with atenolol than with nebivolol or plaimproves large arterial compliance. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] 12 Nebivolol has been shown to enhance left ventricular function cebo (Table 3) .
During double-blind treatment, the only notein patients with cardiac impairment, and to be welltolerated in subjects with cardiac failure. [13] [14] [15] [16] [17] This worthy positive experience was of enhanced wellbeing, reported by 47 patients (15 nebivolol, 12 atenaspect has considerable potential. Many patients with hypertension have concomitant coronary artery olol, 20 placebo).
A total of 285 patients, 151 men and 134 women, disease, and the latter is now the most frequent cause of impaired cardiac function. 18 Further, completed the quality of life questionnaire at baseline and at treatment end-point. For the total patient arterial endothelial damage and dysfunction are thought possibly to be contributory to the pathogengroups, no statistically significant differences were found between the three treatments either for the esis of atherosclerosis (atheroma) in hypertension. 19 Drugs capable of lessening such disorders might summary scales or composite scales. However, in the atenolol group only there was a significant help to limit the arterial complications of hypertension. deterioration (P Ͻ 0.05) from baseline to end-point in response to the query concerning, 'Problems in Nebivolol should thus be a valuable addition to the antihypertensive therapeutic repertoire. While maintaining interest during sex'.
Electrocardiogram confirmed the slight slowing of several of these aspects are at present speculative, the drug merits further study regarding its capacity heart rate in those on the two active drugs, but was otherwise unremarkable. There were no consistent to limit hypertension-related vascular and cardiac disease. or relevant changes in routine biochemical, haematological, or urinary tests at any stage.
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The principal aim of the present study was to establish the efficacy, acceptability and safety of nebivoAgarwala K (Manchester); Agrawal VK (Nuneaton); Bakhru MN (Hertfordshire); Bayman I (Coventry); lol in comparison with the well-established cardioselective beta-blocker atenolol in the treatment of Berger AB (Milton Keynes); Bhaduri PK (Wigan); Bowron P (Bishop Auckland); Brown MR (Glasgow); essential hypertension in UK primary care (general practice). The doses selected of the active drugs, Burman A (Manchester); Dass BK (Manchester); Evans TW (Stirling) ; Fradd SO (Nottingham); Gould 5 mg rather than 10 mg of nebivolol, 10 and 50 mg rather than 100 mg of atenolol, 11 were considered on CHG (Co-Antrim); Guest ND (Cheshire); Hague IU (Manchester); Hossain M (London); Huda ZU (Cothe evidence of the previous dose-response trials quoted, to provide near optimal anti-hypertensive Tyrone); Hughes IW (Liverpool); James IGV (Bolton); Jones BP (Manchester); Kane JA (Surrey); Kapur YP efficacy plus acceptability. These aspects were confirmed, and nebivolol 5 mg once daily was shown to (Clwyd); Khatri CP (Manchester); Kukula MS (Manchester); Lennox B (Ayr); Lone IA be similarly effective to atenolol 50 mg once daily. 
